Uses for medical devices having a lubricious, nitric oxide-releasing coating

Inactive Publication Date: 2002-02-21
MEDTRONIC AVE
View PDF0 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

0078] Antioxidants may be added to the coating mixture to improve oxidative stability of the cured coatings. Antioxidants include, but are not limited to, tris(3,5-di-t-butyl-4-hydroxybenzyl)isocyanurate, 2,2'-methylenebis(4-methyl-6-t-butylphenol), 1,3,5-trimethyl-2,4,6-tris(3-,5-di-t-butyl-4-hydroxybenzyl)benzene, butylhydroxytoluene, octadecyl 3,5-di-t-butyl-4-hydroxyhydrocinnamate, 4,4

Problems solved by technology

However, in many cases the selection of materials does not provide the anti-slip properties desired in conjunction with other desirable properties for the particular medical device.
First, the exact ratio of primer material to the hydrophilic polymer is difficult to control, as it depends on whatever amounts of primer and hydrophilic polymer happen to be deposited by the wet film during the respective coating steps.
Second, the primer may begin to redissolve in the second coating solution, causing some loss of primer and further resulting in difficulty in controlling the primer/hydrophilic polymer ratio.
Third, the hydrophilic polymer is not covalently bonded to the substrate and may bond to other materials in the area leading the coating to lose its desired properties.
Fourth, additional facilities and time are needed for coating with a two step process, as compared to a one step process.
These coatings often lack good durability.
However, the multistep procedure makes it difficult to tailor the properties and values of the final coatings.
The coating formed, however, is not lubricious.
However, the one step coating process is only suitable for polymeric substrates.
Exposure to a medical device which is implanted or inserted into the body of a patient can cause the body tissue to exhibit adverse physiological reactions.
For instance, the insertion or implantation of certain catheters or stents can lead to the formation of emboli or clots in blood vessels.
Similarly, the implantation of urinary catheters can cause infections, particularly in the urinary tract.
Other adverse reactions to medical devices include inflammation and cell proliferation which can lead to hyperplasia, occlusion of blood vessels, platelet aggregation, rejection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example

[0109] A coating solution was prepared by combining the following ingredients and mixing them thoroughly:

[0110] (a) 0.32 g. of an aromatic polyisocyanate adduct based on toluene diisocyanate and dissolved in propylene glycol monomethyl acetate and xylene having an NCO content of about 10.5% and a molecular weight of about 400 available as Desmodur.TM. CB 60 from Bayer Corporation;

[0111] (b) 0.67 g. of a solvent-free, saturated polyester resin (polyol) available as Desmophen.TM. 1800 from Bayer Corporation;

[0112] (c) 0.91 g. of polyethylene oxide available as Polyox.TM. having a molecular weight of about 300,000 from Union Carbide Corp.,

[0113] (d) 76.97 g. acetonitrile;

[0114] (e) 21.82 g. THF; and

[0115] (f) 2.02 g. 3-isocyanyopropyltriethoxysilane available as UCT I7840-KG from United Chemical Technologies, Bristol, Pa.

[0116] Five 18" inch wires were coated with the solution by dipping for 11 seconds. The solvent was evaporated at ambient conditions for approximately 20 minutes. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods are provided for delivering nitric oxide to the vascular tissue of a patient to inhibit or prevent restenosis or improve vascular function following various surgical procedures or associated with various NO-related conditions. The disclosed methods comprise contacting the vascular tissue of a patient with a medical device coated with a coating comprising nitric oxide associated with and releaseable from a polyurea network formed from the reaction on said medical device of a polyisocyanate; an amine donor and/or hydroxyl donor; an isocyanatosilane adduct having terminal isocyanate groups and at least one hydrolyzable alkoxy group bonded to silicon; and optionally a polymer selected from the group consisting of polyethylene oxide, polyvinyl pyrrolidone, polyvinyl alcohol, polyethylene glycol, and polyacrylic acid.

Description

[0001] This application is a continuation-in-part of U.S. application Ser. No. 09 / 405,024, filed Sep. 27, 1999, which is a continuation-in-part of U.S. application Ser. No. 09 / 163,038, filed Sep. 29, 1998, which applications are herein incorporated by reference in their entirety.[0002] 1. Field of the Invention[0003] This invention relates generally to the uses for a drug-coating complex which is drug-releasing in physiological media. More particularly, the invention relates to methods of using medical devices coated with a lubricious, nitric oxide-releasing coating for the treatment of vascular disorders, including restenosis, and the induction of angiogenesis.[0004] 2. Related Art[0005] It has long been known that hydrophilic coatings with low friction (coefficient of friction of 0.3 or less) are useful for a variety of medical devices such as catheters, catheter introducers and the like. When low friction surfaces are used, the devices, upon introduction into the body, slide easi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K33/00A61M31/00A61L27/00A61L27/34A61L27/54A61L29/00A61L29/08A61L29/16A61L31/00A61L31/10A61L31/16A61P9/00A61P9/08A61P9/10A61P9/12A61P11/16A61P13/08A61P31/04
CPCA61L27/34A61L27/54A61L29/085A61L29/16A61L31/10A61L31/16A61L2300/114A61L2300/416A61L2300/606C08L75/04Y10S514/824A61P11/16A61P13/08A61P31/04A61P9/00A61P9/08A61P9/10A61P9/12
Inventor TEDESCHI, EUGENESHAH, CHIRAG B.
Owner MEDTRONIC AVE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products